HSK31858

DRUG3 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

Asthma BronchialeBronchial AsthmaBronchiectasisChronic Obstructive Pulmonary Disease (COPD)Non-cystic Fibrosis Bronchiectasis (NCFBE)

Phase 2

A Study of HSK31858 in Participants with Non-Cystic Fibrosis Bronchiectasis

CompletedNCT05601778

Haisco Pharmaceutical Group Co., Ltd.Non-cystic Fibrosis Bronchiectasis (NCFBE)

Start: 2022-12-06End: 2024-06-07Updated: 2024-09-26

A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma

Enrolling by invitationNCT06637254

Haisco Pharmaceutical Group Co., Ltd.Bronchial Asthma

Start: 2024-10-22End: 2026-09-20Target: 219Updated: 2024-12-24

A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion

Enrolling by invitationNCT06820749

Haisco Pharmaceutical Group Co., Ltd.Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)

Start: 2024-12-10End: 2026-06-22Target: 309Updated: 2025-02-20

Related Papers

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

British Journal of Clinical Pharmacology2025-04-024 citations

Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

2025-03-2512 citations

Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study

European Respiratory Journal2024-09-1047 citations